Become a PROVENGE Provider
The first in a new class of therapy, PROVENGE creates a new opportunity in your treatment of advanced prostate cancer.
PROVENGE is the only autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer and marks a change in the traditional advanced prostate cancer treatment paradigm. Prior to the FDA-approval of PROVENGE, the only approved non-palliative treatment option for men with advanced prostate cancer was taxane-based therapy.
Join colleagues in your region to offer patients with advanced prostate cancer this innovative new treatment option by:
- Click here to register for more information
- Call Dendreon ON Call at 1-877-336-3736
Benefits of Becoming a PROVENGE Provider
Among the benefits of becoming a PROVENGE provider, Dendreon Corporation, the makers of PROVENGE, provides your practice—and your patients—with comprehensive support services throughout the course of therapy. In addition to simplifying the insurance process, Dendreon aids in scheduling procedures, and provides your practice with ongoing product support.
PROVENGE Expands Treatment Options
Become a PROVENGE provider today and help your patients continue their fight against advanced prostate cancer.
If you are not ready to become a provider at this time, you can still help your patients receive this important new therapy. Simply visit the PROVENGE Provider Locator to find the closest provider site.
To receive updates about PROVENGE: register now.
Next: PROVENGE Resources
PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.
In controlled clinical trials, serious adverse events reported in the PROVENGE group included acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.
The most common adverse events (incidence ≥ 15%) reported in the PROVENGE group were chills, fatigue, fever, back pain, nausea, joint ache, and headache.
Please see the Full Prescribing Information.